TherapeuticsMD announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance

TherapeuticsMD, Inc.

Board approves 1-for-50 reverse stock split to cure Nasdaq minimum bid price non-compliance.
Effective May 6, 2022 at 5:00 p.m. ET; post-split trading on Nasdaq under "TXMD" begins May 9, 2022.
No stockholder vote required; fractional shares rounded up to nearest whole share.
Nasdaq granted extension to June 1, 2022 to regain compliance with $1.00 bid price.
Authorized shares reduced from 600 million to 12 million; authorized reduction matches split.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.